CSL
CSL: Plasma Giant - Transformation or Overvaluation?
Updated 17 Nov 2025
CSL trades at $220.29 vs fair value $136.28 (62% premium). Strong plasma oligopoly moat (7.7/10 quality) executing $500M transformation targeting 34% EBITDA margins by FY28. Revenue growth 5.6% CAGR, but current valuation appears to fully reflect optimistic scenarios with limited margin of safety.
View note